Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-03-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2023年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" which translates to "Audit Report". It is issued by a certified public accounting firm (大信会计师事务所) and contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and includes consolidated and parent company financial statements for the year ended December 31, 2023. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report rather than a full annual report or other filing types. Therefore, the document fits the category of Audit Report / Information (AR). FY 2023
2024-03-29 Chinese
关于召开2023年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice for the 2023 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd., detailing the meeting date, voting procedures, agenda items including the 2023 Annual Report and financial reports, and instructions for shareholders to participate. It does not contain the actual annual report or financial statements but rather announces the meeting and the proposals to be voted on. The document length is 4194 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2024-03-29 Chinese
募集资金存放与实际使用情况审核报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report on the use and storage of raised funds by Yunnan Watson Biotechnology Co., Ltd. It is issued by a certified public accounting firm and includes detailed financial data on the raised funds, their management, usage, and compliance with regulatory requirements. The document contains an auditor's opinion, responsibilities of the board and auditors, and detailed financial tables and explanations about the raised funds usage for the year 2023. It is not a full annual report but a specialized audit report focusing on the raised funds. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters. The document is about a specific audit of raised funds usage, not a general annual report or earnings release. Therefore, the correct classification is AR with high confidence. FY 2023
2024-03-29 Chinese
募集资金使用管理制度（2024年3月）
Governance Information Classification · 95% confidence The document is titled '募集资金使用管理制度' which translates to 'Fundraising Capital Usage Management System'. It is a detailed internal policy document outlining the management, storage, usage, supervision, and change procedures related to the company's raised funds. It references regulatory frameworks and internal governance but does not contain financial statements, earnings data, or audit opinions. It is a governance-related document focused on the management and use of capital raised by the company. It is not an announcement, report publication, nor a financial report. Therefore, the best fitting category is 'Governance Information' (CGR), as it details internal rules and governance practices related to capital usage.
2024-03-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Yunnan Watson Biotechnology Co., Ltd. It details the approval of various reports related to the 2023 fiscal year, including the annual report, audited financial report, internal control evaluation report, and profit distribution plan. The document also mentions that these reports are available on the designated disclosure website (巨潮资讯网), indicating that the actual reports are not included here but referenced. The document is relatively short (4586 characters) and serves as an official announcement of the Supervisory Board's meeting decisions and approvals, rather than the full annual report or financial statements themselves. Therefore, it fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement of meeting resolutions and approvals, not the full report or detailed financial data.
2024-03-29 Chinese
关于延期披露公司2023年年度报告的公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (828 characters) from a company about the delay in disclosing its 2023 Annual Report. It states the original disclosure date and the new postponed date, mentions the company's operational status, and references a previously disclosed earnings forecast. There is no actual financial data or the report itself included, only a notice about the timing change. According to the 'MENU VS MEAL' rule, this is an announcement about the report publication, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2024-03-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.